Owlstone Medical has raised £4.9 million ($7 million) to fund the ongoing clinical trials of its diagnostic breathalyzer for lung and colon cancers.
Researchers at Loyola University Chicago say stent retrievers, which can effectively reverse strokes, are revolutionizing the way stroke patients are being treated.
IBM Research in Australia is partnering with Melanoma Institute Australia on identifying melanoma using cognitive technology. The team will conduct research to build on IBM's work with MoleMap. MoleMap uses visual analytics to analyze more than 40,000 data sets that include images and text.
Measuring the twisting motion of the heart prior to mitral valve surgery predicted the outcome for some heart failure patients, a study showed.
Life sciences R&D company PureTech has kept mum on Sonde Health, a company working on a voice-based platform for assessing patient health. But it announced Tuesday that the startup has struck a deal with MIT's Lincoln Lab to license its audio analysis tech that will help Sonde develop its diagnostic tool.
A "bionic" cardiac patch has been developed by researchers at Harvard. Charles Lieber, chair of the Department of Chemistry and Chemical Biology at Harvard, and postdoctoral fellow Xiaochuan Dai co-authored a study regarding the cardiac patch, which was published in Nature Nanotechnology.
Spotlight On... TrapX Labs details evolution of hospital network hackers; Intermountain docs use 3-D printed kidney to determine treatment; Elekta launches novel cervical cancer treatment device; and more...
Georgetown University's Institute for Reproductive Health is recruiting up to 1,200 women for a real-time study of Cycle Technologies' smartphone app that calculates a woman's fertility on a daily basis.
Stealthy MedyMatch emerged in February with plans to improve emergency room care using cognitive analysis and artificial intelligence. Now, in its first collaboration with a U.S. hospital, the company is developing its first real-time decision-support tool using data from New Jersey-based Capital Health.
Avita Medical will gain an additional $7.96 million to support its plans for U.S. market approval and launch of ReCell. This money, from the Biomedical Advanced Research and Development Authority, supplements the $53.9 million contract that went through last September.
Medtronic will add a heart failure implant and pipeline products in its $1.1 billion acquisition of HeartWare. The deal will accelerate the development of HeartWare's products and round out Medtronic's Cardiac Rhythm & Heart Failure division.
San Diego's Epic Sciences has added a new liquid biopsy test to its arsenal of biopharma cancer detection tools that targets homologous recombination deficiencies in individual circulating tumor cells.
Drug adherence player HealthPrize Technologies closed a Series B financing for an undisclosed amount. The company currently uses a "gamification" approach to push drug adherence, but plans to expand into other sectors of the healthcare industry.
Biotech researchers at Cornell University have snagged a $2.3 million grant from the National Institutes for Health to develop the FeverPhone, an app capable of diagnosing febrile diseases like dengue, malaria, chikungunya, typhoid fever, leptospirosis and Chagas disease.
Dr. Stephen Friend, founder of Sage Bionetworks, which developed apps for Apple's ResearchKit, is moving on to work for the tech titan, effective immediately. In addition to his data experience at the open-science nonprofit, he brings 8 years of R&D experience from his time at Merck.
A new stem cell-containing bio-ink could be used to create living tissue through 3D printing, called "bio-printing." The ink was developed by scientists at the University of Bristol, and it could eventually produce complex tissues for surgical implants.
Pinpointing the cause of brain infections and inflammation is challenging, with more than half of cases going undiagnosed. But a Johns Hopkins University team is aiming to change that with next-generation sequencing.
The FDA said it acted properly by accepting late patient injury reports from a Medtronic study that showed problems with its Infuse bone graft, adding that the information provided by the devicemaker was "consistent" with data the regulatory agency already had.
GI Dynamics announced the final results from the U.S. pivotal trial of its endoscopically delivered device to treat Type 2 diabetes and obesity.
A pair of regional insurers has decided that treatment using Nevro's Senza neurostimulation device is experimental and will therefore not reimburse it starting next month. Nevro shares dropped 3% in response to the news Wednesday.